Compare IDEXX Laboratories, Inc. (IDXX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs KeyCorp — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while KeyCorp trades at $20.14 (market cap $21.45B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and KeyCorp pays a 4.08% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and KeyCorp for 66 Days on average.
| IDXX | KEY | |
|---|---|---|
Market Cap | $40.43B | $21.45B |
Volume | 692,164 | 19,450,846 |
Sector | Health | Financials |
52-Week High | $766.68 | $23.99 |
52-Week Low | $504.70 | $16.78 |
Typical Hold Time | 46 Days | 66 Days |
Enterprise Value | $41.32B | $34.63B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
KeyCorp (KEY) trades at $19.83, down 1.54% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank has beaten EPS estimates for three consecutive quarters, with a Q3 2026 estimate of $0.4615. Revenue rebounded to $7.29B in 2025, and the net income margin improved to 26.72%. Recent corporate actions include a $0.21 dividend and key executive appointments in wealth and retail banking.
The outlook is cautiously optimistic, supported by strong analyst consensus (60.79% buy rating) and a $25.00 price target implying 26% upside. Investment opportunities include earnings momentum and shareholder returns via dividends and buybacks. Risks involve interest rate sensitivity, competitive pressures on margins, and macroeconomic uncertainty affecting loan growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
